Gene Liau, EVP Research & Preclinical Development at Stoke Therapeutics, Inc. (STOK), sold 45,076 shares at $40.00 ($1.7M) on 2020-10-16, disclosed to the SEC on 2020-10-20.
Open-market sale of $1.7M STOK by EVP Research & Preclinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.00 | 5,851 | $234K | 13.6% |
| 2 | $37.64 | 24,775 | $933K | 54.2% |
| 3 | $38.42 | 7,225 | $278K | 16.1% |
| 4 | $38.42 | 7,225 | $278K | 16.1% |
| Total | $38.20 avg | 45,076 | $1.7M | 100% |
| Filing → |
| STOK | SELL | 2020-06-03 | $1.0M | — | Filing → |
| STOK | SELL | 2020-05-26 | $225K | — | Filing → |